- Analysts are weighing in on recently public Bind Therapeutics (BIND -1%), whose most advanced drug candidate is BIND-014, a PSMA targeting Accurin containing docetaxel.
- Credit Suisse starts the shares at Outperform. Price target is $21.
- Cowen initiates at Outperform with a $30 price target.
- Stifel starts BIND at Buy. Price target is $20.
- JMP initiates at Market Outperform. Price target is $30.
at Zacks.com (Nov 10, 2014)